Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![DigitalMoreco Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::437691517.png) DigitalMore.co 📱ดิจิตอลมอร์ [@DigitalMoreco](/creator/twitter/DigitalMoreco) on x 8031 followers
Created: 2025-07-17 00:53:41 UTC

Nature Medicine Published Phase X Results of Innovent Biologics’ Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma 


![](https://pbs.twimg.com/media/GwBUmrlWcAAsoCj.png)

XX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1945648064800112809/c:line.svg)

**Related Topics**
[$1801hk](/topic/$1801hk)

[Post Link](https://x.com/DigitalMoreco/status/1945648064800112809)

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

DigitalMoreco Avatar DigitalMore.co 📱ดิจิตอลมอร์ @DigitalMoreco on x 8031 followers Created: 2025-07-17 00:53:41 UTC

Nature Medicine Published Phase X Results of Innovent Biologics’ Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

XX engagements

Engagements Line Chart

Related Topics $1801hk

Post Link

post/tweet::1945648064800112809
/post/tweet::1945648064800112809